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Objectives: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China’s aging population. However, representative data on the eco-
nomic burden of osteoporosis fractures are lacking. The aims of this study were to 
estimate direct outpatient medical costs, indirect costs and family burden associ-
ated with patients with osteoporosis fractures in China. MethOds: One hundred 
and fifty osteoporosis fracture patients and/or care-givers were interviewed within 
149 days [median] post-fracture in three tertiary hospitals in Beijing, Wuhan and 
Chongqing representing eastern, middle and western China. Fracture patients were 
discharged from hospital between January 2011 and January 2013. The survey col-
lected data on demographics; ambulatory status; outpatient services and costs 
(emergency room, drugs, other outpatient); indirect medical services and supplies 
and costs (nursing, transportation, rehabilitation, devices, etc.); and lost work time 
from caregivers. Results: Of the 123 valid respondents (female: 64.2%; mean age: 
71.3 years), 62.6% were hip fractures, followed by vertebral fracture (34.1%), non-
vertebral/non-hip fracture (2.4%), and multiple fracture (0.8%). All patients received 
surgical treatment, 8.9% had historical fractures, 80.5% had comorbidities and 82.9% 
of patients had post-discharge outpatient visits. The most frequent comorbidities 
were hypertension (61.0%), rheumatoid arthritis (41.5%), high cholesterol (35.0%) and 
cardiovascular disease (34.2%). Reported disability (walk w/aid or could not walk) 
increased from 13% pre-fracture to 36% post-fracture. Average post-acute outpatient 
care costs and indirect medical costs were 2084 RMB and 3526 RMB, respectively. 
Care-givers reported an average of 33.2 days lost from work. Using median income 
from the three regions, the estimated average lost income for caregivers was 5910 
RMB (weighted by share of responders per region). cOnclusiOns: The study sug-
gests the economic burden of osteoporosis fractures is considerable in terms of 
outpatient medical costs, indirect medical costs and family burden. Osteoporosis-
related fractures may pose a significant burden to China due to the aging population.
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Objectives: Provide clinically relevant evidence and drug expenditure informa-
tion for brazilian public health system management. MethOds: We performed a 
systematic review on the use of anti-TNF biological agents, infliximab, adalimumab 
and etanercept in the treatment of patients with rheumatoid arthritis, using the 
precepts of evidence-based medicine, ensuring methodological quality of clinical 
studies, prioritizing clinical outcomes. Clinical evidence was retrieved in PubMed, 
Central Cochrane, EMBASE and medicine purchase costs in July 2010. Results: 
Twenty-three randomized trials met the eligibility criteria, six on infliximab, nine 
on adalimumab and eight on etanercept. Adalimumab and etanercept showed no 
benefits when not associated with methotrexate. The ACR50 response to infliximab 
(NNT = 6) and adalimumab (NNT = 5) were similar while the results for etanercept 
were considered heterogeneous. The annual cost of infliximab to treat six patients 
and get ACR50 response in a single patient was US$ 125,997.00 while for adalimumab 
to treat five was US$ 186,990.00. The ACR70 response was similar between etanercept 
(NNT = 9) and adalimumab (NNT = 10), being lower in the recommended dose of 
infliximab (NNT = 12). The most favorable annual cost of acquisition was observed 
with adalimumab which US$ 311,651.00 is needed to treat 10 patients and get ACR70 
response in a single one, compared to expense of US$ 365,107.00 with etanercept 
(NNT = 9). The unusual infliximab dose of 10mg/kg showed similar results (NNT 
= 9), however with the most unfavorable spent of US$ 680,385.00. cOnclusiOns: 
Adalimumab was the agent who showed the most favorable annual expenditure 
for medicine purchase from the perspective of the public health system in Brazil, 
considering the most clinically relevant response.
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Objectives: To examine the pattern of biological treatment and the medical costs 
for patients with rheumatoid arthritis (RA). MethOds: A longitudinal dataset that 
includes the claims of service used by a cohort of RA patients from the Bureau of 
National Health Insurance was used for this study. The inclusion criteria for the 
study cases were patients who: 1) were holding the Catastrophic Illness Card with 
RA; 2) had the 1stline TNF-α antagonist treatments for at least 6 months; 3) were aged 
over 17. Treatment patterns were defined based on their TNF-α Antagonist within 
12 months after the initial 6-month treatment period. Wilcoxon signed rank tests 
were performed to compare differences in service costs and service uses between 
the pre- and post-biological treatment periods. Results: In total, 2425 patients 
were eligible for analysis. In the first year after TNF-α initial 6-month treatment, 94% 
remained using the same TNF-α antagonist, 3% had switched from one to another 
TNF-α antagonist, and 3% discontinued use of TNF-α antagonist. RA patients treated 
with TNF-α antagonist were significantly associated with reductions in emergency 
room visits (p < 0.001), hospital days (p < 0.01) and total medication costs (excluding 
biologics) (p < 0.01). However, total RA-related outpatient visits and overall medi-
cation costs went up significantly (p < 0.001). Reduction in services use was not 
productive age (18-60 for women and 18-65 for men) were recruited at regionally 
stratified sample of rheumatology outpatient centers around the country and 
were offered a questionnaire including Work Productivity and Activity Impairment 
(WPAI) instrument (a standardized tool for loss of work productivity estimation). 
The survey was complemented by disease activity assessment questionnaire 
filled out by specialists who were also responsible for patients recruitment dur-
ing the routine visits. Employed patients were estimating i.a. the absenteeism 
and presenteeism rates (% of work time missed due to health and % of impair-
ment while working). Subsequently, systematic review of Medline database was 
conducted. Two studies using WPAI questionnaire were found (Bansbrack 2012, 
Zhang 2010). Results: In the study, mean age of RA patients was 49 (mean age 
at RA onset was about 39), mean DAS28 result 3,77 (moderate disease). 40% of the 
group had first symptoms for less than 5 years (mean duration since symptoms 
onset was 90 months). Meanwhile, in Bansbrack 2012 mean age at RA onset was 
48 and mean duration since onset of symptoms was 48.6 months. Mean age of 
patients described in Zhang 2010 was 51, 45.8% had disease duration of less than 
5 years. The participants had a low function disability level and moderate arthritis. 
In the study absenteeism rate was 18%, while presenteeism rate reached 27%. The 
corresponding values in Bansbrack 2012 were 8.7% and 24%. In Zhang 2010 only 
presenteeism rate was analyzed and equaled 17.8%. cOnclusiOns: RA reduces 
work ability and lower work productivity in people in productive age both in Poland 
and in other countries. Differences in patients characteristics are probably the 
cause of results variation between studies.
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Objectives: Available data on economic impact of hip fractures in the U.K. are 
mostly derived from clinical trials or published before the year 2000; recent esti-
mates are lacking. This study examined health care resource usage, treatment and 
costs among patients with hip fracture in the U.K. MethOds: The study used data 
from the Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode 
Statistics (HES). Adult patients hospitalised for hip fracture (ICD-10: S72 or M84.4; 
admission date as index date between January 1, 2006—March 31, 2011) and no pre-
vious hip fracture 7 days to 1 year pre- index, and computerised data available 1 year 
pre and 1 year post-index were identified in HES. Hip fracture-related inpatient and 
outpatient visits and pharmaceutical treatments were estimated for pre- and post-
index periods. Associated costs were calculated by multiplying resource units by 
official publicly available costs from the NHS perspective. Results: A total of 8,028 
hip fracture patients were identified (mean age 79; 27% age 85+; 75.8% female; mean 
Charlson comorbidity index score 2.1). The most common comorbidities were osteo-
arthritis (42%), pulmonary disease (25%), and renal disease (23%). Pre-index, aver-
age resource use per patient included 1 inpatient stay (mean 5.7 days), 7.4 General 
surgery visits, 4.4 blood tests, and 0.76 General Practice phone consults. Average 
overall costs pre-index were £3122. For the index hospitalisation, mean length-
of-stay and costs were 19.5 days and £14223, respectively; 18% were discharged to 
another hospital; and 39% and 5% had partial or total hip arthroplasty procedures 
performed. Post-index frequent medications included acetaminophen (56%), opioids 
(46%), and bisphosphonates (46%); 51% had hospital stays; and 5.7% had subsequent 
hip fractures. Average post-index overall costs were £7359. cOnclusiOns: Our 
study provides recent estimates of resource usage, treatment and costs among 
U.K. hip fracture patients. This information can be useful in burden of illness and 
economic analyses.
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Objectives: Total hip arthroplasty (THA) is a commonly performed surgical proce-
dure in the elderly, projected to increase substantially due to the aging population. 
Newer resource use and cost estimates are needed to understand the potential THA 
burden. The study objective was to estimate health care resource use and costs in 
THA patients in the U.K. MethOds: The Clinical Practice Research Datalink (CPRD) 
linked to the Hospital Episode Statistics (HES) was used to estimate resource use in 
THA patients. Inclusion criteria were: first inpatient stay for THA (OPCS procedure 
code W37-W39, W46-W48, W93-W95) (index event between 1/1/2006--3/31/2011); 
no THA diagnosis/procedure 7 days to one year pre-index date; 1-year pre and 
1-year post-index of computerised data available; age 18+. Inpatient, outpatient 
and pharmacy THA-related costs were calculated by multiplying resource units 
by official publicly available costs (British Pound Sterling, 2012) from the NHS per-
spective. Results: THA patients identified (n= 15,288) were mostly female (66%), 
elderly (mean age 72; 45%> 75), and 84% had osteoarthritis. Pre-index, the most 
common medications were opioids (53%), NSAIDs (41%), and acetaminophen (35%); 
95% had General surgery visits; 64% had inpatient stays; 36% had x-ray; and overall 
costs (std. dev) were £4,556 (7850). The index hospital event average length-of-stay 
(LOS) was 9 days and mean costs were £11,321. Post-index medication usage for 
opioids, NSAIDs, and acetaminophen was 49%, 29%, and 45%, respectively. The 
most frequent resources were General surgery visits (94%), hospital stays (39%), 
and General Practice phone consults (35%). For patients with utilisation, means per 
patient were 7.4 for General surgery visits, 5.4 days for hospitalisations. Mean (std. 
dev) overall post-index costs were £3,567 (9612), comprised mostly of inpatient costs 
(85%). cOnclusiOns: This study described resource utilisation, pain medications 
usage and associated costs for THA patients. These estimates may offer a better 
understanding of the economic burden.
